PainLive

PainLive PainLive.com is committed to delivering top stories and videos from key opinion leaders in the field of pain management.

PainLive is the official Website for the publication Pain Management. The mission of PainLive and the publication is to provide pain professionals with the resources and information they need to provide the best patient care. We will be covering every angle of the pain management practice, from new technology to treatment advances to important regulatory decisions. PainLive.com adds features and tools not possible with print, such as social media feeds, blogs, video interviews with key opinion leaders on PainLive TV, and live coverage from major pain meetings. As we move ahead, we will continually look for new and better ways to deliver pain management news as quickly and efficiently as possible. It is an exciting time for pain research and treatment, and we look forward to being your link to everything in pain management. PainLive is the most comprehensive portal on the Web for today's busy healthcare professional.

: Emergency medicine specialist urges hospitals to add methylnaltrexone to the hospital formulary after promising resea...
06/10/2022

: Emergency medicine specialist urges hospitals to add methylnaltrexone to the hospital formulary after promising research shows the treatment's success with opioid-induced constipation.

Emergency medicine specialist urges hospitals to add methylnaltrexone to the hospital formulary after promising research shows the treatment's success with opioid-induced constipation.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups...
06/03/2022

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.

Presence of chronic liver disease, prior use of gabapentin and being discharged to a long-term hospital or rehabilitatio...
05/27/2022

Presence of chronic liver disease, prior use of gabapentin and being discharged to a long-term hospital or rehabilitation center are among some of the factors associated with a new opioid use disorder diagnosis

Presence of chronic liver disease, prior use of gabapentin and being discharged to a long-term hospital or rehabilitation center are among some of the factors associated with a new opioid use disorder diagnosis.

: Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients u...
05/13/2022

: Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients undergoing a bunionectomy.

Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients undergoing a bunionectomy.

Emergency medicine specialist urges hospitals to add methylnaltrexone to the hospital formulary after promising research...
05/06/2022

Emergency medicine specialist urges hospitals to add methylnaltrexone to the hospital formulary after promising research shows the treatment's success with opioid-induced constipation.

Emergency medicine specialist urges hospitals to add methylnaltrexone to the hospital formulary after promising research shows the treatment's success with opioid-induced constipation.

A new method of opioid disposal was proposed by the FDA in an attempt to mitigate unauthorized access to opioids and les...
04/29/2022

A new method of opioid disposal was proposed by the FDA in an attempt to mitigate unauthorized access to opioids and lessen risk of addiction.

A new method of opioid disposal was proposed by the FDA in an attempt to mitigate unauthorized access to opioids and lessen risk of addiction.

Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients unde...
04/22/2022

Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients undergoing a bunionectomy.

Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients undergoing a bunionectomy.

: The CDC is encouraging public feedback on updated guideline recommendations for opioid prescribers for the first time...
04/15/2022

: The CDC is encouraging public feedback on updated guideline recommendations for opioid prescribers for the first time since 2016.

The CDC is encouraging public feedback on updated guideline recommendations for opioid prescribers for the first time since 2016.

The NaV1.8 inhibitor VX-548 shows promising potential as a non-opioid acute pain treatment.
04/08/2022

The NaV1.8 inhibitor VX-548 shows promising potential as a non-opioid acute pain treatment.

The NaV1.8 inhibitor VX-548 shows promising potential as a non-opioid acute pain treatment.

While recent data indicate the potential to reduce opioid overdose mortality rates with naloxone distribution, authors c...
04/01/2022

While recent data indicate the potential to reduce opioid overdose mortality rates with naloxone distribution, authors call for increased support for those who witness an overdose.

While recent data indicate the potential to reduce opioid overdose mortality rates with naloxone distribution, authors call for increased support for those who witness an overdose.

The Director of Policy and Advocacy for the US Pain Foundation addresses the important changes made to the updated draft...
03/25/2022

The Director of Policy and Advocacy for the US Pain Foundation addresses the important changes made to the updated draft of the CDC Clinical Practical Guideline for Prescribing Opioids 2022.

The Director of Policy and Advocacy for the US Pain Foundation addresses the important changes made to the updated draft of the CDC Clinical Practical Guideline for Prescribing Opioids 2022.

Mindfulness-oriented recovery enhancement is unlike other mindfulness-based treatments and was found superior to support...
03/16/2022

Mindfulness-oriented recovery enhancement is unlike other mindfulness-based treatments and was found superior to supportive group psychotherapy for treating opioid misuse and chronic pain.

Mindfulness-oriented recovery enhancement is unlike other mindfulness-based treatments and was found superior to supportive group psychotherapy for treating opioid misuse and chronic pain.

Address

Plainsboro, NJ
08536

Website

Alerts

Be the first to know and let us send you an email when PainLive posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to PainLive:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category